Plozasiran for High Triglycerides
(MUIR-3 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia (HTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo and be evaluated for efficacy and safety.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop your current medications, but you must be on standard lipid-lowering medications unless you are intolerant. It's best to discuss your specific medications with the trial team.
What safety data exists for Plozasiran (ARO-APOC3) in humans?
The safety of drugs targeting apolipoprotein C-III, like volanesorsen, has been evaluated in clinical trials for lowering triglycerides. These trials suggest that such treatments can effectively reduce triglyceride levels, but specific safety data for Plozasiran (ARO-APOC3) is not detailed in the provided research.12345
How is the drug Plozasiran different from other treatments for high triglycerides?
Plozasiran is unique because it targets apolipoprotein C-III (apoC-III), a protein that regulates triglyceride levels, using an antisense oligonucleotide approach to reduce its production, which is different from traditional treatments like statins or omega-3 fatty acids that do not specifically target apoC-III.12367
What data supports the effectiveness of the drug Plozasiran for high triglycerides?
Research indicates that targeting apolipoprotein C-III (apoC-III) can effectively lower triglyceride levels, which are linked to cardiovascular disease risk. Drugs that inhibit apoC-III, like those in development, have shown promise in reducing triglycerides and associated cardiovascular risks.12389
Are You a Good Fit for This Trial?
Adults with high triglycerides who have a stable blood sugar level (HbA1c ≤8.5%), can maintain a low-fat diet, and have LDL cholesterol levels within specific limits. Participants must have documented hypertriglyceridemia with certain fasting triglyceride levels, be on standard lipid-lowering medications unless intolerant.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 4 doses of plozasiran or placebo by subcutaneous injection once every 3 months
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Plozasiran
Find a Clinic Near You
Who Is Running the Clinical Trial?
Arrowhead Pharmaceuticals
Lead Sponsor